MX2018007377A - Composicion de acido hialuronico para inyecciones en el pene. - Google Patents
Composicion de acido hialuronico para inyecciones en el pene.Info
- Publication number
- MX2018007377A MX2018007377A MX2018007377A MX2018007377A MX2018007377A MX 2018007377 A MX2018007377 A MX 2018007377A MX 2018007377 A MX2018007377 A MX 2018007377A MX 2018007377 A MX2018007377 A MX 2018007377A MX 2018007377 A MX2018007377 A MX 2018007377A
- Authority
- MX
- Mexico
- Prior art keywords
- hyaluronic acid
- acid composition
- relates
- composition
- penile
- Prior art date
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title abstract 4
- 229920002674 hyaluronan Polymers 0.000 title abstract 4
- 229960003160 hyaluronic acid Drugs 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000002347 injection Methods 0.000 title abstract 3
- 239000007924 injection Substances 0.000 title abstract 3
- 210000003899 penis Anatomy 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere al campo del agrandamiento del pene y a las composiciones de ácido hialurónico para su use en la forma de inyecciones en el pene. La misma también se refiere a la penoplastia que usa una inyección de ácido hialurónico. La misma se refiere rads particularmente a una composición que comprende al menos un -ácido hialurónico reticulado, usada en el tratamiento del síndrome de vestidor y caracterizada porque se administra en una dosis de al menos 0.15 mlicm2, y porque la composición se administra repetidamente, con una primera administración que es seguida por n administración(es) subsiguiente(s) espaciadas por un intervalo de tiempo entre 6 y 20 meses, con n > 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2015/080110 WO2017102001A1 (fr) | 2015-12-16 | 2015-12-16 | Composition d'acide hyaluronique pour injections peniennes |
| PCT/EP2016/081624 WO2017103241A1 (fr) | 2015-12-16 | 2016-12-16 | Composition d'acide hyaluronique pour injections peniennes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018007377A true MX2018007377A (es) | 2018-11-09 |
Family
ID=54979674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018007377A MX2018007377A (es) | 2015-12-16 | 2016-12-16 | Composicion de acido hialuronico para inyecciones en el pene. |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20180361019A1 (es) |
| EP (1) | EP3389675A1 (es) |
| JP (1) | JP2019500429A (es) |
| KR (1) | KR20180102097A (es) |
| CN (1) | CN109789157A (es) |
| MX (1) | MX2018007377A (es) |
| WO (2) | WO2017102001A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2989114T3 (es) * | 2015-11-10 | 2024-11-25 | Perito Paul E | Composición para uso en un método terapéutico no quirúrgico de aumento del perímetro del pene |
| WO2020095079A1 (fr) * | 2018-11-06 | 2020-05-14 | Kylane Laboratoires Sa | Composition injectable contenant de l'acide hyaluronique pour des applications au niveau du corps |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4200080A1 (de) | 1992-01-03 | 1993-09-30 | Reinmueller Johannes | Pharmazeutische Zusammensetzung zur Wund-, Narben- und Keloidbehandlung |
| GB9902412D0 (en) | 1999-02-03 | 1999-03-24 | Fermentech Med Ltd | Process |
| FR2861734B1 (fr) | 2003-04-10 | 2006-04-14 | Corneal Ind | Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus |
| JP4157889B2 (ja) * | 2003-06-25 | 2008-10-01 | 有限会社 循環器研究所 | 性交機能改善用外用製剤 |
| CN1287870C (zh) * | 2003-09-17 | 2006-12-06 | 启东致远生物科技有限公司 | 阴茎增长植入物 |
| FR2895907B1 (fr) | 2006-01-06 | 2012-06-01 | Anteis Sa | Gel viscoelastique a usage dermatologique |
| FR2924615B1 (fr) | 2007-12-07 | 2010-01-22 | Vivacy Lab | Hydrogel cohesif biodegradable. |
| FR2951368B1 (fr) | 2009-10-16 | 2012-11-16 | Jacques Derhy | Implants volumetriques cosmetiques du penis |
| FR2983483B1 (fr) | 2011-12-02 | 2014-11-14 | Vivacy Lab | Procede de substitution et reticulation simultanees d'un polysaccharide via ses fonctions hydroxyles |
| FR2991876B1 (fr) | 2012-06-13 | 2014-11-21 | Vivacy Lab | Composition, en milieu aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate |
| FR2994846B1 (fr) * | 2012-08-29 | 2014-12-26 | Vivacy Lab | Composition, sterilisee, comprenant au moins un acide hyaluronique et de l'ascorbyl phosphate de magnesium |
| EP2764847A1 (en) | 2013-02-08 | 2014-08-13 | Kirch Urologie B.V. | Penile augmentation |
-
2015
- 2015-12-16 WO PCT/EP2015/080110 patent/WO2017102001A1/fr not_active Ceased
-
2016
- 2016-12-16 US US16/063,360 patent/US20180361019A1/en not_active Abandoned
- 2016-12-16 MX MX2018007377A patent/MX2018007377A/es unknown
- 2016-12-16 JP JP2018551499A patent/JP2019500429A/ja active Pending
- 2016-12-16 WO PCT/EP2016/081624 patent/WO2017103241A1/fr not_active Ceased
- 2016-12-16 CN CN201680080928.2A patent/CN109789157A/zh active Pending
- 2016-12-16 EP EP16816664.3A patent/EP3389675A1/fr not_active Withdrawn
- 2016-12-16 KR KR1020187020398A patent/KR20180102097A/ko not_active Withdrawn
-
2020
- 2020-08-31 US US17/007,533 patent/US20200397944A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180102097A (ko) | 2018-09-14 |
| WO2017102001A1 (fr) | 2017-06-22 |
| WO2017103241A1 (fr) | 2017-06-22 |
| CN109789157A (zh) | 2019-05-21 |
| US20200397944A1 (en) | 2020-12-24 |
| EP3389675A1 (fr) | 2018-10-24 |
| JP2019500429A (ja) | 2019-01-10 |
| US20180361019A1 (en) | 2018-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202102906B (en) | Liquid protein formulations containing viscosity-lowering agents | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| PE20190205A1 (es) | Uso de inhibidores de miostatina y terapias de combinacion | |
| MY188749A (en) | Compositions comprising a combination of nivolumab and ipilimumab | |
| MY190855A (en) | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof | |
| MX375745B (es) | Composicion para el tratamiento de la diabetes que comprende conjugado de analogo de insulina de accion prolongada y conjugado de peptido insulinotropico de accion prolongada. | |
| MX2017008569A (es) | Derivados de glucagon con estabilidad mejorada. | |
| CA3030422C (en) | Stabilizing excipients for therapeutic protein formulations | |
| MX390570B (es) | Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo. | |
| MX2019007088A (es) | Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos. | |
| MY192813A (en) | Aqueous formulation comprising paracetamol and ibuprofen | |
| MX2022007908A (es) | Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv. | |
| AR120290A1 (es) | Una forma de dosificación parenteral estable de acetato de cetrorelix | |
| MX2019011620A (es) | Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos. | |
| MX2018007377A (es) | Composicion de acido hialuronico para inyecciones en el pene. | |
| MX2020007222A (es) | Metodos para el tratamiento de afecciones inflamatorias de la piel. | |
| MX374938B (es) | Un método para el tratamiento de trastornos del movimiento con befiradol. | |
| BR112022004723A2 (pt) | Formulações de insulina e glucagon injetáveis por via subcutânea e métodos de administração | |
| BR112018012439A2 (pt) | ?composição compreendendo, pelo menos, um ácido hialurônico reticulado, utilizada no tratamento da síndrome do vestiário? | |
| MY203965A (en) | Injectable formulations of paracetamol | |
| ZA202202673B (en) | Methods and compositions for treating endometriosis | |
| EA201700347A3 (ru) | Средство для эффективного купирования острого и/или хронического болевого синдрома и способ его применения | |
| CO2018001531A2 (es) | Lisobactina para su uso en el tratamiento de la mastitis bovina | |
| UA120529U (uk) | Спосіб збереження функції нирок у хворих, що страждають на подагру і метаболічний синдром | |
| UA115063U (xx) | Спосіб лікування собак із больовим синдромом при панкреатиті |